Nektar Therapeutics (NASDAQ:NKTR), a research-based, development stage biopharmaceutical company, announced yesterday that it has named John Northcott as its new senior vice president and chief commercial officer.
Northcott will also serve as a member of the company's Executive Committee reporting directly to president and CEO, Howard W Robin.
The company says that Northcott is a proven leader who brings extensive commercial experience to Nektar, including both pre-launch planning and on-market commercialisation in oncology and other therapeutic areas.
Most recently, he served as the chief commercial officer of Pharmacyclics from 2015 to 2019. From 2007 to 2013, he also held commercial roles in both US and Global marketing for Avastin with Genentech and the Roche Group, having most recently served as International Business Leader for Avastin, leading global product strategy initiatives in oncology. He also has experience in a variety of therapeutic areas from earlier commercial leadership and management positions at other pharmaceutical companies including Lexicon, Merck and Pfizer.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval